Land: Israel
Sprache: Englisch
Quelle: Ministry of Health
VISMODEGIB
ROCHE PHARMACEUTICALS (ISRAEL) LTD
CAPSULES
VISMODEGIB 150 MG
PER OS
Required
HOFFMANN LA ROCHE, SWITZERLAND
ERIVEDGE® is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation
2018-02-28
Important information for men and women taking Erivedge regarding contraception and contraceptives ERIVEDGE PREGNANCY PREVENTION PROGRAMME • Erivedge could cause serious birth defects and death of the unborn or newborn child. • You or your partner must not become pregnant during treatment with this medicine. • You must follow the contraception guidelines presented in this brochure. Introduction: This brochure contains a summary of important safety information and guidelines about taking Erivedge. Read it carefully and keep it in case you will want to read it in the future. Use Erivedge in accordance with your doctor’s instructions. Also read the Patient Package Insert attached to the medicine package for important information about taking the medicine. If there is anything that you don’t understand or if you have additional questions, please ask the doctor or pharmacist. THIS BROCHURE IS NOT A SUBSTITUTE FOR THE PATIENT PACKAGE INSERT ATTACHED TO THE PREPARATION. FOR FULL INFORMATION ABOUT THE MEDICINE, SEE THE PATIENT PACKAGE INSERT ATTACHED TO THE PREPARATION. TABLE OF CONTENTS: 1. Introduction 1.1 What is Erivedge and how does it work? 2. Who may not take Erivedge? 3. Biological mechanisms and the risk for birth defects 4. Before you begin taking Erivedge 5. During and after treatment: 6. Pregnancy and Erivedge 6.1 If you are a woman of childbearing potential taking Erivedge 6.2 If you are a man taking Erivedge 6.3 If pregnancy is suspected 7. Side effects of Erivedge 1. INTRODUCTION • Erivedge could cause serious birth defects and death of the unborn or newborn child. • You or your partner must not become pregnant during treatment with this medicine. • You must follow the contraception guidelines presented in this brochure. Read the explicit instructions given to you by your doctor, particularly about the effect of Erivedge on unborn children. 1.1 WHAT IS ERIVEDGE AND HOW DOES IT WORK? Erivedge is an anti-cancer medicine, containing the active ingredient vismodegib. It is used in adults to tre Lesen Sie das vollständige Dokument
1 Erivedge PI version 8 ERIVEDGE ® Vismodegib CAPSULES 150 MG 1. NAME OF THE MEDICINAL PRODUCT Erivedge 150 mg hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each hard capsule contains 150 mg of vismodegib. Excipient with known effect: Each hard capsule contains 71.5 mg lactose monohydrate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Hard capsule (capsule). Pink coloured opaque body marked “150 mg” and a grey opaque cap marked “VISMO” with black ink. The size of the capsule is ‘Size 1’ (dimensions 19.0 x 6.6 mm). 4. CLINICAL PARTICULARS Educational material In order to assist health care providers and patients to avoid embryonic and foetal exposure to Erivedge the Marketing Authorisation Holder will provide educational materials (Erivedge Pregnancy Prevention Programme) to reinforce the potential risks associated with the use of Erivedge: HCP (HEALTH CARE PROVIDER) INFORMATION CARD This product is marketed with HCP information card providing important safety information. Please ensure you are familiar with this material as it contains important safety information. PATIENT INFORMATION CARD AND BROCHURE This product is marketed with patient safety information materials (patient information card and patient brochure ). Please explain to the patient the implications of this treatment including the need for compliance. Please also explain the signs of important adverse reactions and instruct the patient when to seek medical care. 4.1 THERAPEUTIC INDICATION Erivedge is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION 2 Erivedge should only be prescribed by or under the supervision of a specialist physician experienced in the management of the approved indication. Posology The recommended dose is one 150 mg capsule taken once daily. Mis Lesen Sie das vollständige Dokument